閉経期の熱に対するニューロキニン3受容体の抗作用
Alexander N Comninos1, Waljit S Dhillo1
1Section of Endocrinology & Investigative Medicine, Imperial College London, London, UK; Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK.
Cell
|August 4, 2023
まとめ
閉経時の熱帯は フェゾリネタントで治療できます FDAが承認した新しい非ホルモン薬です このNK3受容体アンタゴニストは,衰弱させる熱帯炎の管理のために,更年期ホルモン療法 (MHT) に有効な代替手段を提供します.
科学分野:
- 生殖内分泌学と薬理学
- 熱調節の神経内分泌学
背景:
- 閉経時の熱帯は,多くの女性に影響を与える 蔓延し,破壊的な症状です.
- 閉経期ホルモン療法 (MHT) は有効ですが,リスクと副作用があり,その広範な適用を制限しています.
- 更年期症状に対する安全で効果的な非ホルモン療法が必要である.
研究 の 目的:
- 閉経期の熱帯炎症に対する新しい治療戦略としてNK3受容体対抗を導入する.
- フェゾリネタントのFDA承認を 強調する為に
- 臨床前研究から臨床応用への移行について議論する.
主な方法:
- NK3受容体アンタゴニストの作用メカニズムのレビュー
- フェゾリネタントの有効性と安全性を裏付ける臨床試験データ
- ニューロキニン3受容体とのフェゾリネタントの相互作用に関する薬理学的研究.
主要な成果:
- フェゾリネタントは,更年期における発熱の頻度と重症度を効果的に軽減します.
- 非ホルモン作用のメカニズムは,従来のMHTと異なる.
- 臨床試験で実証された安全性および耐受性プロファイル.
結論:
- NK3受容体の抗作用は 更年期における熱帯炎症の管理における 画期的な進歩を表しています
- フェゾリネタントは熱中症から救済を求める女性にとって重要な非ホルモン治療の選択肢です.
- この進歩は 更年期症状管理の パラダイムシフトを意味しています
関連する概念動画
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
199
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
199
01:28Menopause
201
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
201
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
243
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
243
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
332
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
332
01:26Cholinergic Antagonists: Therapeutic Uses
776
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
776
01:28Cholinergic Antagonists: Pharmacological Actions
1.2K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.2K